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Cancer, a disease of the genome, is caused by a combination of germ-line predisposing variants 
and acquired somatic mutations. A unified view of heritable and acquired genetic factors will 
improve our understanding of cancer occurrence and progression. Fanfani, Stracquadanio, and 
coworkers provide new insight into heritable cancer risk through a computational method that 
identifies genes and loci that contribute strongly to cancer heritability; many of these loci also 
harbor somatic drivers. Beyond improving cancer clinical outcomes, these methods will also be 
valuable across complex disorders by identifying regions responsible for missing heritability. 
 See related article by Fanfani et al., p. XXXX. 
 
Cancer is a disease of the genome. Cancer risk arises from a combination of heritable 
genetic variants, often tagged by single-nucleotide polymorphisms (SNPs), and acquired somatic 
mutations. Genome-wide association studies (GWAS) have revealed many of the heritable 
variants, and tumor sequencing studies have identified many somatic drivers classified broadly as 
oncogenes and tumor suppressor genes. The cost of a genome sequence is now comparable to the 
cost of other clinical diagnostics, on the scale of the cost of a visit to the doctor’s office itself. 
Better knowledge of germ-line risk factors and their relationship to somatic mutations should lead 
to advances in clinical care, similar to advances in prenatal genetic screening in which cell-free 
fetal DNA sequencing is now more informative and less risky than long-used invasive diagnostics. 
Why, then, does knowledge of germ-line risk remain murky? 
 Murky is quantifiable as the heritable risk that remains unexplained. Overall heritability 
can be estimated readily from epidemiological studies of monozygotic and dizygotic twins, as well 
as other family-based studies. Heritability for a disease-related phenotype typically ranges from 
25% to 75%. For many diseases, however, only a small portion of the heritability is explained by 
genome-wide significant SNPs. Clearly some of this heritability is due to smaller genetic effects 
that have not reached genome-wide significance, the conventional threshold being a p-value below 
5x10–8. These smaller effects, which result in association test statistics that are biased to be slightly 
larger than predicted by a null distribution, have been difficult to disentangle from population 
stratification, cryptic relatedness, and other confounding factors that also inflate test statistics. 
 Distinguishing smaller polygenic effects contributing to heritability from confounding 
biases is possible through methods such as linkage disequilibrium score regression (1), which uses 
summary data SNP-phenotype regression coefficients and SNP-SNP correlations, defined as a 
population-specific linkage disequilibrium (LD) matrix, to deconvolute true polygenic effects 
from spurious confounders. These methods often involve explicit or implicit inversion of the LD 
matrix, which is numerically unstable when individual SNPs are low frequency or pairs of SNPs 
are highly correlated. Subsequent methods use quadratic forms and regularization by singular 
value decomposition to estimate heritability that can be ascribed to smaller genetic effects in 
aggregate, without requiring the responsible SNPs to be identified directly (2). These methods, 
applied broadly across phenotypes, demonstrated that conventionally significant GWAS SNPs 
account for only a small portion of the heritability. Depending on the phenotype, smaller effects 
within GWAS loci may on aggregate contribute as much as the significant effects. Weak effects 
spread throughout the genome account for additional heritability that is also missed by 
conventional analyses. When combined, these smaller effects can yield a five-fold to ten-fold 
increase in the heritability ascribed to genetic factors. For many traits, this genetic heritability can 
explain half or more of the upper limit of the total heritability estimated from epidemiology. 
 Fanfani, Stracquadanio, and coworkers now provide further insights into the relationship 
between heritable cancer risk genes inferred from germ-line GWAS and cancer driver genes 
implicated by tumor somatic mutation sequencing (3). Their advance improves LD score 
regression by localizing GWAS heritability estimates to individual genes. Their method also 
exposes many of the hidden assumptions of previous approaches, including effect size distributions 
and genome-wide heritability estimates, which are incorporated as explicit distributions within a 
hierarchical probability model. Efficient sampling yields posterior estimates of per-gene 
heritability to converge on a set of genes with high probability (>99%, with higher thresholds 
possible with longer computation time) of contributing heritability beyond the genome-wide null. 
 Naming their method Bayesian Gene HERitability Analysis (BAGHERA), they then 
applied it comprehensively to cancers with GWAS summary data available from the UK Biobank. 
Notably, they were able to apply this method even to rarer cancers, where population sizes limit 
the power of conventional GWAS. Their method is also able to analyze heritability for late-onset 
cancers, where, relative to early-onset cancers, germ-line variants are less important than acquired 
somatic mutations (4), making heritability more difficult to study. 
 Their approach has created a resource of high confidence cancer heritability genes, 
numbering approximately one thousand, that complements a core set of somatic driver genes (5) 
and a larger set of somatic driver mutations identified from collaborative pan-cancer analyses (6). 
These cancer heritability genes provide substantially new information: only about 5% are known 
somatic cancer drivers. Nevertheless, they coincide with many known cancer hallmark pathways, 
many are implicated in multiple cancers, and overall explain 10% of heritable cancer risk. As 
cohort sizes increase, methods such as BAGHERA should continue to identify a greater fraction 
of the heritable risk of cancer. 
 Improved genetic risk assessment could improve clinical treatment by identifying 
individuals at greatest risk and prioritizing them for closer monitoring. Clinical benefit depends on 
incidence as well as heritability, which suggest that risk scores generated from knowledge of 
heritable genetic factors could have earliest benefit for cancers of the breast, colon, and prostate 
(7). The anticipated benefit also depends on the effect size distribution from weaker polygenic 
effects, another output of the BAGHERA model. 
The heritable cancer genome may also be important in linking cell proliferation and tumor 
growth, the stereotypical phenotypes associated with cancer, with metastatic phenotypes including 
invasion, dissemination, seeding, and outgrowth. Metastases, rather than primary tumors, are 
responsible for the majority of tumor deaths. Cancer-risk GWAS SNPs are already known to link 
to tissue-specific gene regulatory networks (8), which may be relevant to processes hijacked by 
tumors to reorganize the local tissue architecture to create an environment more permissive to 
metastasis. 
 Methods such as BAGHERA will have broad impact across heritable diseases in general 
by highlighting loci with strong aggregate causal genetic factors. These loci can be further 
analyzed using existing gene-based methods that resolve an overall association signal into the most 
likely independent effects (9). Identifying the mechanism behind a genetic association is an 
outstanding challenge, particularly given the success of GWAS for quantitative traits whose 
cohorts are effectively much larger than for low-incidence diseases. Computational methods that 
analyze GWAS SNPs and genes in the context of biological networks, including gene regulation 
as mentioned above and also extending to signal transduction, protein-protein interactions more 
generally, and metabolic networks, can help prioritize candidate mechanisms for experimental 
tests, and drug repurposing studies can provide fast validations for many proteins that are drug 
targets in other contexts (10). 
In summary, the advances represented by Fanfani et al. and related work provide a view of 
the heritable genetic risk genes. The implicated genes provide new context for understanding the 
role of somatic drivers and could reveal relationships between initial malignant transformation, 
involving oncogenic and tumor-suppressor phenotypes most closely associated with somatic 
drivers, and subsequent progression and metastasis responsible for mortality. 
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